PA-PMI
19.8.2020 17:02:05 CEST | Business Wire | Press release
Project Management Institute (PMI), the world's leading association for the project management profession, invites professionals across the globe to register for Virtual Experience Series titled, “The Community: Together We Rise ” on 25 August 2020 from 11 a.m. - 5 p.m. Eastern Daylight Time. The second event in this innovative series is headlined by comedian and host of The Daily Show ® program Trevor Noah, and hosted by journalist, talk show host, and executive producer, Tamron Hall. Additionally, more than 20 industry experts will lead thought-provoking sessions, including artificial intelligence thought leader and author of Girl Decoded: A Scientist’s Quest to Reclaim Our Humanity by Bringing Emotional Intelligence to Technology , Dr. Rana el Kaliouby.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200819005404/en/
The Virtual Experience Series connects participants with global innovators, inspirational voices, and project leaders to help them navigate a world defined by challenge, and embrace the opportunity to make a new reality. In the opening session, Trevor Noah will discuss how he taps into his inner project manager to galvanize a community, practice agility daily, and lead a global team. In 2015, Trevor succeeded long-time program host, Jon Stewart, and has received various accolades, including a Primetime Emmy Award win. In response to COVID-19, Trevor began hosting a modified virtual version of The Daily Show called The Daily Social Distancing Show with Trevor Noah to continue tackling the biggest stories in news, politics and pop culture. This year, The Daily Show received eight Emmy nominations.
Participants who want to boost their career or pivot to a new one can discover the Brand You Hub containing useful tips for all professionals looking to adapt and thrive in this new dynamic work environment. They can also network with project professionals in the Networking Hub and join a fireside chat with leaders of Fortune 500 organizations to explore the human side of leading during disruption, as well as lessons and takeaways from the pandemic.
“Now more than ever, PMI’s goal is to bring to the forefront insights and resources that are essential to help empower people to move projects forward and turn ideas into reality,” said Michael DePrisco, vice president, global experience & solutions at PMI. “In our post-COVID new work ecosystem, teams are putting increased emphasis on collaborative leadership and empathy to help deliver value in our virtual workplace. These are what we refer to as ‘power skills’ and PMI is here to provide the resources necessary to build and perfect these skillsets.”
Each month, the Virtual Experience Series will feature a new roster of thought-leading personalities and industry experts. Upcoming series dates and topics include:
- 9 September - A Deep Dive in Organizational Agility: Adaptability, Resilience and Learning
- 20 October - The World: Our Global Impact
- 12 November - A Deep Dive in Business Analysis: Drawing a Map to the Future
- 9 December - The Future: Forging Our Path Forward
Registration for PMI members is $99 for a single experience or $359 for the entire series. Registration for non-members is $149 for a single experience or $899 for the event series. Purchasing a series pass includes complimentary on-demand access to the PMI® Talent and Technology Symposium, which took place in June, and select recorded sessions for attendees to peruse through January 2021. Each session is eligible for professional development units (PDUs) toward maintaining PMI® certifications.
For more information on this event and to register, visit experience.pmi.org .
About Project Management Institute (PMI)
Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Through global advocacy, collaboration, education and research, we work to prepare more than three million professionals around the world for The Project Economy: the coming economy in which work, and individuals, are organized around projects, products, programs and value streams. Now 50 years in the making, we work in nearly every country around the world to advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com® website creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at www.PMI.org , www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute .
“The Daily Show” is a registered mark of Comedy Partners.
“PMI” and “Projectmanagement.com” are registered marks of Project Management Institute, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200819005404/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom